ArriVent BioPharma To Reveal Two Preclinical Posters On The EGFR Inhibitor Firmonertinib And On the Novel Dual-target MUC16/NaPi2b Tetravalent ADC ARR-002 At The 2026 AACR Annual Meeting

ArriVent BioPharma, Inc. (NASDAQ: AVBP) announced two poster presentations at the 2026 AACR Annual Meeting, scheduled for April 17-22 in San Diego. The presentations will feature preclinical findings on the EGFR inhibitor firmonertinib, which is currently in a pivotal Phase 3 study for non-small cell lung cancer, and the novel dual-target MUC16/NaPi2b tetravalent ADC ARR-002, which has shown superior anti-tumor activity in ovarian cancer models. The data highlights the potential of these therapeutics in advancing cancer treatment.